Watching EyeCRO! When you look for the best in contract research, you want to see the highest of high tech capabilities. Testing the preclinical efficacy and pharmacokinetics of polymer based drug depots for the retina is not for the faint of heart, and it isn’t your grandma’s ophthalmic test beds. Only the most capable, only the most advanced team of multifield experts is going to cut it. In vitro and in vivo testing of retinopathy treatments is serious science, and I want to see capabilities down to the 100 nm range for nanoparticle synthesis and formulation, I want to see advanced polymer capabilities, and treatments that continue to deliver way past a window of a few days or weeks, I want to see long term delivery curves, out to six months. Picking a CRO is serious business, and choosing a team for development of treatments for vitreous and retinal issues requires vision at a level of granularity that is rare, if not unheard of. You want to see that your team has not only the ability to formulate workable treatments, but to formulate the proper preclinical trials to validate those treatments, and then the historical awareness of vehicle suitability, to ensure a lead candidate selection process and a formulation suitable for your needs. When you’re looking for serious expertise in incorporated hydrophobic drugs with the ability to tailor the drug loading from 10% to 40% w/w, you actually don’t have to look very far. When I want to see excellence in ophthalmics, I look at EyeCRO.